Due to health issues, this site is no longer maintained and will be shut down shortly.

LMNL Liminal BioSciences Inc.

Liminal BioSciences, Inc. is a biopharmaceutical corporation. The firm engages in the development of therapeutic products focusing on unmet medical needs in the field of fibrosis, autoimmune disease or inflammation and cancer. It operates through the following segments: Bioseparations, Plasma-derived Therapeutics, and Small Molecule Therapeutics. The Bioseparations segment offers prometic's core bioseparation technologies and products. The Plasma-derived Therapeutics segment provides efficient extraction and purification of therapeutic proteins from human plasma. The Small Molecule Therapeutics segment manufactures drug candidates such as PBI-4050, PBI-4547, and PBI-4425. The company was founded on October 14, 1994 and is headquartered in Laval, Canada.

Note: This is not a U.S. company, but they cross-list their shares on a U.S. stock exchange - see the related symbol CT:LMNL.

$3.88  +0.07 (1.92%)
As of 03/24/2023 16:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  
IPO date:  11/19/2019
Outstanding shares:  31,042,560
Average volume:  10,984
Market cap:   $118,272,154
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      40-F
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy